Biogen Can't Block Mylan MS Drug Launch During IP Appeal
The Federal Circuit on Thursday paved the way for Mylan to launch its forthcoming generic version of Biogen's top-selling multiple sclerosis drug Tecfidera while Biogen appeals the invalidation of a patent...To view the full article, register now.
Already a subscriber? Click here to view full article